Cytek director exercises RSUs, gets new option grant

Cytek Biosciences director Imper Vera increased her equity stake through compensation-related awards.

Rhea-AI Filing Summary

Cytek Biosciences director Imper Vera increased her equity stake through compensation-related awards. On June 10, 2026, she exercised 43,973 Restricted Stock Units that had fully vested the same day, receiving an equal number of common shares and bringing her direct common stock holdings to 59,679 shares.

She also received grants of 18,261 director stock options with a $4.05 exercise price expiring on June 10, 2036, and 33,333 new Restricted Stock Units. Both the new option and RSU awards vest 100% on the earlier of June 10, 2027 or Cytek’s 2027 annual meeting of stockholders, if that meeting is held in June 2027. No open-market buys or sales were reported.

Insider Trade Summary

43,973 shares exercised/converted

Exercise 4 txns

Insider Imper Vera

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	33,333	$0.00	$0.00
Grant/Award	Director Stock Option (right to buy)	18,261	$0.00	$0.00
Exercise	Restricted Stock Units	43,973	$0.00	$0.00
Exercise	Common Stock	43,973	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 33,333 contracts (Direct); Director Stock Option (right to buy) — 18,261 contracts (Direct); Common Stock — 59,679 shares (Direct)

Footnotes (4)

1. F1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
2. F2. 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).
3. F3. 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).
4. F4. 100% of the shares subject to the RSU Award vested on June 10, 2026.

Key Figures

RSUs exercised into common stock: 43,973 shares Common shares held after transactions: 59,679 shares Director stock options granted: 18,261 options at $4.05 +3 more

6 metrics

RSUs exercised into common stock 43,973 shares Restricted Stock Units exercised on June 10, 2026

Common shares held after transactions 59,679 shares Direct Cytek Biosciences common stock holdings post-transaction

Director stock options granted 18,261 options at $4.05 Grant on June 10, 2026; expires June 10, 2036

New RSUs granted 33,333 units Grant on June 10, 2026, vesting by June 10, 2027 or 2027 annual meeting

Vesting date of prior RSU award June 10, 2026 100% of shares under the earlier RSU Award vested on this date

Vesting schedule for new awards By June 10, 2027 New RSUs and option vest earlier of June 10, 2027 or 2027 annual meeting in June

Key Terms

Restricted Stock Unit, Director Stock Option (right to buy), vesting, annual meeting of stockholders, +1 more

5 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Director Stock Option (right to buy) financial

"Director Stock Option (right to buy) with an exercise price of 4.0500"

vesting financial

"100% of the shares subject to the RSU Award vested on June 10, 2026."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders"

exercise price financial

"Director Stock Option ... with a conversion or exercise price of 4.0500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Imper Vera report for Cytek Biosciences (CTKB)?

Imper Vera reported compensation-related equity activity, not open-market trading. She exercised 43,973 vested Restricted Stock Units into common shares and received new grants of 18,261 director stock options and 33,333 Restricted Stock Units, all dated June 10, 2026, increasing her overall equity exposure.

How many Cytek Biosciences (CTKB) shares does Imper Vera hold after this Form 4?

After these transactions, Imper Vera directly holds 59,679 shares of Cytek Biosciences common stock. This reflects the receipt of 43,973 shares from vested Restricted Stock Units exercised on June 10, 2026, and indicates a larger continuing ownership position following the reported equity awards.

What stock options were granted to Imper Vera by Cytek Biosciences (CTKB)?

Imper Vera received 18,261 director stock options with a $4.05 exercise price. These options are exercisable into Cytek Biosciences common stock and expire on June 10, 2036. The entire option award vests on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting, if held in June.

What new Restricted Stock Units did Imper Vera receive from Cytek Biosciences (CTKB)?

She was granted 33,333 new Restricted Stock Units, each representing a contingent right to one Cytek Biosciences common share. All units vest 100% on the earlier of June 10, 2027 or the 2027 annual meeting of stockholders, provided that meeting occurs in June 2027, aligning vesting with board service.

Did Imper Vera sell any Cytek Biosciences (CTKB) shares in this Form 4?

No sales were reported. The Form 4 shows only acquisitions: an exercise of 43,973 Restricted Stock Units into common stock and grants of 18,261 stock options plus 33,333 Restricted Stock Units. There were zero open-market buy or sell transactions disclosed in this filing.

When did Imper Vera’s previously granted Cytek Biosciences RSUs vest?

Footnotes state that 100% of the shares subject to the earlier Restricted Stock Unit award vested on June 10, 2026. That same day, Imper Vera exercised 43,973 vested units into an equal number of Cytek Biosciences common shares, increasing her direct stock holdings accordingly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 07:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Imper Vera

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CALIFORNIA 94538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		M		43,973	A	(1)	59,679	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/10/2026		A		33,333		(2)	(2)	Common Stock	33,333	$0	33,333	D
Director Stock Option (right to buy)	$4.05	06/10/2026		A		18,261		(3)	06/10/2036	Common Stock	18,261	$0	18,261	D
Restricted Stock Units	(1)	06/10/2026		M			43,973	(4)	(4)	Common Stock	43,973	$0	0	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).

3. 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).

4. 100% of the shares subject to the RSU Award vested on June 10, 2026.

	/s/ Valerie Barnett, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)